Cosmos Health Commences U.S. Operations, Entering $164B Nutraceuticals Market with Its Sky Premium Life Brand; Expects 75% Gross Margins and Strong Cash Flow, with NOOR Collagen Alone Projected to Generate Over $12M in Annualized Revenue
Cosmos Health (NASDAQ:COSM) has launched its U.S. operations by introducing its Sky Premium Life food supplements brand, marking its entry into the $164B U.S. nutraceuticals market. The company's first product, NOOR Collagen, is manufactured in FDA-registered, GMP-certified U.S. facilities.
The company projects 75% gross margins and expects NOOR Collagen alone to generate over $12M in annualized revenue. The U.S. nutraceuticals market is forecasted to grow at a 6.2% CAGR through 2030, driven by increasing health awareness and demand for natural wellness solutions.
This strategic expansion includes local manufacturing to mitigate tariff exposure and logistical risks, with plans for additional product launches to meet U.S. consumer demand.
Cosmos Health (NASDAQ:COSM) ha avviato le operazioni negli Stati Uniti presentando il marchio di integratori Sky Premium Life, entrando nel mercato statunitense dei nutraceutici da 164 miliardi di dollari. Il primo prodotto NOOR Collagen è prodotto in impianti negli USA registrati dalla FDA e certificati GMP. L'azienda prevede margini lordi del 75% e si aspetta che NOOR Collagen da solo generi oltre 12 milioni di dollari di ricavi annualizzati. Il mercato nutraceutico USA è previsto crescere a un tasso di crescita annuale composto del 6,2% entro il 2030, trainato da una maggiore consapevolezza della salute e dalla domanda di soluzioni naturali per il benessere. Questa espansione strategica prevede la produzione locale per mitigare l'esposizione ai dazi e i rischi logistici, con piani per ulteriori lanci di prodotti per soddisfare la domanda dei consumatori statunitensi.
Cosmos Health (NASDAQ:COSM) ha lanzado sus operaciones en EE.UU. presentando su marca de suplementos Sky Premium Life, marcando su entrada en el mercado estadounidense de nutracéuticos, valorado en 164 mil millones de dólares. El primer producto, NOOR Collagen, se fabrica en instalaciones en EE. UU. registradas por la FDA y certificadas GMP. La compañía proyecta márgenes brutos del 75% y espera que NOOR Collagen por sí solo genere más de 12 millones de dólares en ingresos anualizados. Se prevé que el mercado nutracéutico de EE. UU. crezca a una CAGR del 6,2% hasta 2030, impulsado por una mayor concienciación de la salud y la demanda de soluciones naturales de bienestar. Esta expansión estratégica incluye fabricación local para mitigar la exposición a aranceles y riesgos logísticos, con planes para lanzamientos de productos adicionales para satisfacer la demanda de los consumidores estadounidenses.
Cosmos Health(NASDAQ:COSM)이 Sky Premium Life 식품 보충제 브랜드를 도입함으로써 미국 사업을 시작했고, 1640억 달러 규모의 미국 뉴트래슈티컬 시장에 진입했다. 회사의 첫 제품 NOOR Collagen은 FDA 등록 및 GMP 인증 미국 시설에서 제조된다. 회사는 총이익률 75%를 예상하며 NOOR Collagen만으로도 연간 매출이 1,200만 달러 이상을 창출할 것으로 기대한다. 미국 뉴트래슈티컬 시장은 2030년까지 연평균 6.2% 성장할 것으로 전망되며, 건강 인식 증가와 천연 웰니스 솔루션에 대한 수요가 이를 견인한다. 이러한 전략적 확장에는 관세 노출과 물류 위험을 완화하기 위한 현지 생산이 포함되며, 미국 소비자 수요를 충족하기 위한 추가 제품 출시 계획이 있다.
Cosmos Health (NASDAQ:COSM) a lancé ses opérations aux États-Unis en présentant sa marque de compléments alimentaires Sky Premium Life, marquant son entrée sur le marché américain des nutraceutiques, évalué à 1640 milliards de dollars. Le premier produit de l'entreprise, NOOR Collagen, est fabriqué dans des installations américaines enregistrées par la FDA et certifiées GMP. L'entreprise prévoit des marges brutes de 75% et s'attend à ce que NOOR Collagen seul génère plus de 12 millions de dollars de revenus annualisés. Le marché américain des nutraceutiques devrait croître à un taux de croissance annuel composé de 6,2% jusqu'en 2030, soutenu par une prise de conscience croissante de la santé et la demande de solutions naturelles de bien-être. Cette expansion stratégique comprend une fabrication locale pour réduire l'exposition tarifaire et les risques logistiques, avec des projets de lancer d'autres produits pour répondre à la demande des consommateurs américains.
Cosmos Health (NASDAQ:COSM) hat seine Aktivitäten in den USA aufgenommen, indem es seine Marke Sky Premium Life für Nahrungsergänzungsmittel vorstellt und so in den 164 Milliarden Dollar schweren US-Nutraceuticals-Markt eingetreten ist. Das erste Produkt des Unternehmens, NOOR Collagen, wird in FDA-registrierten, GMP-zertifizierten US-Anlagen hergestellt. Das Unternehmen prognostiziert Bruttomargen von 75% und erwartet, dass NOOR Collagen allein über 12 Millionen US-Dollar an annualisierten Umsätzen generiert. Der US-Markt für Nutraceuticals wird voraussichtlich bis 2030 mit einer CAGR von 6,2% wachsen, getrieben von wachsendem Gesundheitsbewusstsein und der Nachfrage nach natürlichen Wellness-Lösungen. Diese strategische Expansion umfasst lokale Fertigung zur Minderung von Zöllen und logistischen Risiken, mit Plänen für weitere Produktlancierungen, um der Nachfrage der US-Verbraucher gerecht zu werden.
تطلق Cosmos Health (بورصة ناسداك: COSM) عملياتها في الولايات المتحدة من خلال تقديم علامتها التجارية Sky Premium Life للمكملات الغذائية، مما يمثل دخولها إلى سوق النوتراكوتيك الأمريكي بقيمة 164 مليار دولار. المنتج الأول للشركة NOOR Collagen، يُصنع في مرافق أميركية مسجّلة لدى FDA ومعتمدة GMP. تتوقع الشركة هامش إجمالي قدره 75% وتتوقع أن يحقق NOOR Collagen وحده أكثر من 12 مليون دولار من الإيرادات السنوية المعلنة. من المتوقع أن ينمو سوق المكملات الغذائية الأمريكية بمعدل نمو مركب قدره 6.2% حتى 2030، مدفوعاً بالتزايد في الوعي الصحي والطلب على حلول العافية الطبيعية. تشمل هذه التوسعة الاستراتيجية التصنيع المحلي لتخفيف التعرض للتعريفات والمخاطر اللوجستية، مع خطط لإطلاق منتجات إضافية لتلبية الطلب الأمريكي.
Cosmos Health（NASDAQ:COSM）已通过推出 Sky Premium Life 食品补充剂品牌进入美国业务，进入1640亿美元的美国营养保健品市场。公司的首款产品 NOOR Collagen 在获FDA注册、GMP认证的美国工厂生产。公司预计毛利率为75%，预计 NOOR Collagen 单独将带来超过1200万美元的年化收入。美国营养保健品市场预计到2030年将以6.2%的复合年增长率增长，推动因素包括健康意识提高和对自然健康解决方案的需求。这一战略扩张包括本地制造以降低关税暴露和物流风险，并计划推出更多产品以满足美国消费者的需求。
- Entry into $164B U.S. nutraceuticals market with projected 6.2% CAGR through 2030
- High gross margins of approximately 75% expected from U.S. operations
- NOOR Collagen projected to generate over $12M in annualized revenue
- Local U.S. manufacturing eliminates tariff exposure and cross-border logistics risks
- FDA-registered, GMP-certified, and UL-audited manufacturing facilities ensure product quality
- Entering highly competitive U.S. nutraceuticals market as a new player
- Revenue projections based on early sales data may not materialize
Insights
Cosmos Health's entry into the $164B US nutraceuticals market with 75% margins could significantly boost revenue if projections materialize.
Cosmos Health's expansion into the $163.7 billion US nutraceuticals market represents a potentially significant growth catalyst for the company. The projected
The company strategically established local manufacturing in GMP-certified, FDA-registered facilities, which serves multiple purposes: ensuring regulatory compliance, maintaining quality control, and eliminating tariff exposure and cross-border logistical challenges. While local manufacturing may have higher production costs than offshore alternatives, this approach is aligned with premium market positioning.
Their initial product launch of NOOR Collagen is projected to generate over
What's particularly notable is the company's emphasis on this being the first in a series of planned US product introductions, suggesting a phased expansion strategy to build their American market presence. The success of this expansion will ultimately depend on execution, particularly around distribution channel development and marketing effectiveness – neither of which are detailed in the announcement.
If Cosmos can achieve its projected margins and revenue targets, this US market entry could meaningfully impact the company's overall financial performance by providing access to the world's largest nutraceuticals market with a locally manufactured premium product line.
CHICAGO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the commencement of its U.S. operations with the launch of its proprietary Sky Premium Life food supplements brand.
All Sky Premium Life products sold in the United States are manufactured locally in GMP-certified, FDA-registered, and UL-audited U.S. facilities, underscoring the Company’s commitment to regulatory excellence and product integrity while mitigating tariff exposure and cross-border logistical risks.
Sales are already underway for Sky Premium Life NOOR Collagen, a proprietary product formulated with premium marine collagen tripeptide, currently available in capsule form and featuring a clinically validated formula designed to support skin and joint health.
The Company anticipates strong gross margins of approximately
According to Grand View Research, the U.S. nutraceuticals market was valued at
Greg Siokas, CEO of Cosmos Health, stated: "We are very pleased to officially commence U.S. operations with the launch of Sky Premium Life NOOR. Early sales momentum is encouraging, and we expect a significant revenue boost from our U.S. operations. This launch marks an important milestone in Cosmos’ expansion strategy as we establish our footprint in the world’s largest nutraceuticals market, supported by local manufacturing capabilities. Sky Premium Life NOOR Collagen is the first step in a series of planned U.S. product introductions that reflect our commitment to scientifically validated, high-efficacy formulations. We expect our U.S. business to become a key growth driver, reinforcing Cosmos’ position as a global healthcare innovator.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. Such forward-looking statements include, but are not limited to, the Company’s expectation that accumulation of ETH will enhance long-term shareholder value through increasing ETH-per-share, the Company’s plans to explore additional yield-generating strategies to optimize cash flow and utility from ETH holdings, that the Facility will provide access to growth capital to support a range of strategic initiatives, including accelerated product development, advanced R&D innovation, enhanced commercial initiatives, and the Company’s planned entry into U.S. manufacturing and the anticipated use of proceeds. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d7277e15-9fd5-4ad2-8c62-d116146556dc
FAQ
What is Cosmos Health's projected revenue for NOOR Collagen in the U.S. market?
What are the expected gross margins for Cosmos Health's Sky Premium Life U.S. operations?
How big is the U.S. nutraceuticals market that COSM is entering?
Where are Cosmos Health's Sky Premium Life products manufactured for the U.S. market?
What is COSM's first product launch in the U.S. market?
